Amphastar Pharmaceuticals Inc - Company Profile
Powered by
All the data and insights you need on Amphastar Pharmaceuticals Inc in one report.
- Save hours of research time and resources with
our up-to-date Amphastar Pharmaceuticals Inc Strategy Report
- Understand Amphastar Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
Amphastar Pharmaceuticals Inc (Amphastar), is a specialty pharmaceutical company that develops, manufactures, and markets generic and proprietary injectable, intranasal and inhalation products. It sells insulin-active pharmaceutical ingredient products. The company’s key products include enoxaparin sodium injection; cosyntropin for injection; naloxone hydrochloride (HCl) injection and phytonadione injection; lidocaine jelly; amphadase hyaluronidase injection; epinephrine, naloxone, phytonadione, primatene mist and glucagon. Amphastar offers its products to alternate care sites, hospitals, clinics and doctors’ offices and long-term care facilities. The company markets its products through subsidiaries, specialty distributors, wholesalers and retailers in the US, the UK, France and China. Amphastar is headquartered in Rancho Cucamonga, California, the US.
Amphastar Pharmaceuticals Inc premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Amphadase (hyaluronidase injection, USP) | Amphadase |
Cortrosyn (cosyntropin Injection) | Luer-Jet |
Critical Care Drugs and Non-Critical Care Drugs | UltraSafe |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Acquisitions/Mergers/Takeovers | In June, the company completed the acquisition of BAQSIMI from Eli Lilly and Company. |
2022 | Regulatory Approval | In May, the company announced it received the approval from the US FDA, for its Abbreviated New Drug Application (ANDA) Regadenoson injection which is a single dose pre-filled Syringe. |
2022 | Regulatory Approval | In April, the company announced it received the approval for its Abbreviated New Drug Application (ANDA) Ganirelix Acetate Injection from the US FDA. |
Competitor Comparison
Key Parameters | Amphastar Pharmaceuticals Inc | Pfizer Inc | Sanofi | Eli Lilly and Co | Teva Pharmaceutical Industries Ltd |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | France | United States of America | Israel |
City | Rancho Cucamonga | New York | Paris | Indianapolis | Tel Aviv |
State/Province | California | New York | Ile-de-France | Indiana | Tel Aviv |
No. of Employees | 1,761 | 88,000 | 87,994 | 43,000 | 35,001 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Mary Ziping Luo, Ph.D. | Chairman; Chief Scientist; Chief Operating Officer | Executive Board | 2005 | 73 |
Jack Yongfeng Zhang, Ph.D. | Chief Scientific Officer; President; Chief Executive Officer; Director | Executive Board | 2020 | 76 |
William J. Peters | Executive Vice President - Finance; President - International Medication Systems, Limited; Director; Treasurer; Chief Financial Officer | Executive Board | 2022 | 55 |
Jacob Liawatidewi | Director; Executive Vice President - Sales and Marketing, and Corporate Administration Center | Executive Board | 2014 | 49 |
Tony Marrs | Executive Vice President - Regulatory Affairs; President - Armstrong Pharmaceuticals; Executive Vice President - Clinical Operations | Senior Management | 2018 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer